The next competitive front in crop protection is intellectual property, not chemistry: a race is underway to lock up patent rights around RNA interference (RNAi) biopesticides, according to an analysis published by Lexology.

RNAi-based products work differently from conventional synthetic chemistry. Rather than attacking a pest through broad toxic activity, they silence specific genes inside the target organism. That specificity is the technology's core agronomic and regulatory selling point, and it is now driving an acceleration in patent filings, licensing strategy and freedom-to-operate disputes across the input sector.

What is driving the IP race?

Lexology frames the competition as a land grab. Companies that secure broad, early patent claims on RNAi constructs, delivery systems and target gene sequences can effectively gatekeep the technology for competitors — and for growers who will eventually buy the resulting seed treatments and sprayable products.

For farm margins, the stakes are straightforward. Input costs for novel modes of action typically carry premium pricing at launch, and exclusive IP positions extend the window in which a maker can hold that premium before generics or competing platforms enter. The patent landscape that firms build now will shape product pricing and availability in the field for years.

The race also has a regulatory dimension. Biopesticides based on RNAi are positioned as lower-risk alternatives to synthetic insecticides, a trait that can shorten review timelines and ease residue and export-tolerance pressures — advantages that make the underlying patents more valuable, not less.

Why should growers and agribusiness follow patent filings?

Patent activity is a leading indicator of product pipelines. filings in this space signal which pests, crops and delivery methods input makers believe will reach commercial scale first.

For cooperatives, distributors and farm-supply retailers, the IP picture matters for another reason: freedom-to-operate conflicts among patent holders can delay launches, fragment product availability by region, or force rebranding and relicensing deals — all of which ripple into what sits on the shelf and at what price.

Lexology's analysis positions RNAi as a next-generation crop protection platform whose commercial trajectory will be decided as much in patent offices as in field trials. The winners of this race will be those who combine defensible claims on the technology with workable routes to registered, manufacturable products.

The report's forward message for the agribusiness sector is clear: watch the patent docket, because the control points for RNAi crop protection are being established now, well before the bulk of the technology reaches widespread commercial acreage.

(This article is based on a headline summary; the full Lexology analysis was not available at publication time. Readers should treat specific filing counts, company names and case references as unverified until the complete report is reviewed.)